EVFMEvofem Biosciences, Inc.

About Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. (EVFM) is a Biotechnology company headquartered in San Diego, CA, United States whose shares trade over-the-counter on the OTCQB tier.

Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, PHEXXI® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. In July 2024, Evofem acquired global rights to its second women’s health product, SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. Evofem re-launched SOLOSEC in the U.S. in November 2024, leveraging its commercial infrastructure and strong physician relationships For more information, visit evofem.com, phexxi.com or sololsec.com.

Products and services

Evofem currently derives revenue from two FDA-approved commercial products. PHEXXI is a hormone-free, on-demand prescription contraceptive vaginal gel indicated in the U.S. for pregnancy prevention. It is also approved in Nigeria. Regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico; filing is expected in the UAE in the first half of 2025 by our GCC commercial partner, Pharma 1. SOLOSEC provides a complete course of therapy to treat two common sexual health infections, bacterial vaginosis (BV) and trichomoniasis, with just one orally-administered dose.

EVFM key facts

Ticker symbol

EVFM

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

San Diego, CA, United States

Country of incorporation

US

Year of incorporation

2014

Employees

32

Estimated market cap

$1.02M (as of Apr 9, 2025)

Shares outstanding

113,356,354

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Evofem Biosciences, Inc. leadership

• Saundra Lee Pelletier — CEO
• Ivy Zhang — CFO, Secretary
• Amy Raskopf — IR, Business Development
• Accounts Payable — Other
• Ellen Thomas — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with E